Log in to search using one of your social media accounts:

 

Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin
AbstractIntroductionTreatment guidelines recommend a stepwise approach to glycemia management in patients with type 2 diabetes (T2D), but this may result in uncontrolled glycated hemoglobin A1c (HbA1c) between steps. This retrospective analysis compared clinical and economic outcomes among patients with uncontrolled T2D initiating two oral antidiabetes drugs (OADs), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), or basal insulin in a real-world setting.MethodsAdults with T2D on OAD monotherapy were identified in the MarketScan claims database (2007 –2014). Those initiating two OADs (simultaneously or sequenti...
Source: Diabetes Therapy - April 19, 2018 Category: Endocrinology Source Type: research

A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1 –2 Oral Anti-Diabetic Drugs
ConclusionOverall, once-weekly semaglutide 1.0  mg as an add-on to 1–2 OADs is the most efficacious GLP-1 RA in terms of the reduction of HbA1c and weight from baseline after 6  months of treatment. In addition, the analysis suggests that once-weekly semaglutide is well tolerated and not associated with an increase in discontinuations due to AEs compared with other GLP-1 RAs.FundingNovo Nordisk. (Source: Diabetes Therapy)
Source: Diabetes Therapy - April 19, 2018 Category: Endocrinology Source Type: research

A Computer-Based Glucose Management System Reduces the Incidence of Forgotten Glucose Measurements: A Retrospective Observational Study
ConclusionsThis computer-based blood glucose monitoring system is useful for the management of glucose monitoring in hospitals.FundingJohnson& Johnson Japan. (Source: Diabetes Therapy)
Source: Diabetes Therapy - April 17, 2018 Category: Endocrinology Source Type: research

Characteristics, Treatment Patterns, and Economic Outcomes of Patients Initiating Injectable Medications for Management of Type 2 Diabetes Mellitus in Japan: Results from a Retrospective Claims Database Analysis
ConclusionsIn Japan, most T2DM patients initiated injectable antidiabetics with specialists vs. GPs. There were considerable differences in characteristics of patients treated by specialists vs. GPs. After initiation, injectable antidiabetics were largely prescribed by GPs. Future research should evaluate the factors associated with different provider practices and communication channels between specialists and GPs to improve patient management.FundingEli Lilly and Co. (Source: Diabetes Therapy)
Source: Diabetes Therapy - April 16, 2018 Category: Endocrinology Source Type: research

A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus
AbstractBasal-bolus therapy (BBT) refers to the combination of a long-acting basal insulin with a rapid-acting insulin at mealtimes. Basal insulin glargine 100 U/mL and prandial insulin lispro have been available for many years and there is a substantial evidence base to support the efficacy and safety of these agents when they are used in BBT or basal-plus therapy for patients with type 1 or type 2 diabetes mellitus (T1DM, T2DM). With the growing availability of alternative insulins for use in such regimens, it seems timely to review the data regarding BBT with insulin glargine 100 U/mL and insulin lispro. In patients wit...
Source: Diabetes Therapy - April 13, 2018 Category: Endocrinology Source Type: research

Adherence to Basal Insulin Therapy Among People with Type 2 Diabetes: A Retrospective Cohort Study of Costs and Patient Outcomes
ConclusionsResults of this study illustrate that despite higher drug costs, there are disease-specific and all-cause cost offsets and improved patient outcomes associated with adherence to basal insulin therapy for people with T2D.FundingEli Lilly and Company. (Source: Diabetes Therapy)
Source: Diabetes Therapy - April 11, 2018 Category: Endocrinology Source Type: research

Early ( ≤ 30 Days), Late (31–360 Days) and Very Late ( & gt;  360 Days) Stent Thrombosis in Patients with Insulin-Treated versus Non-Insulin-Treated Type 2 Diabetes Mellitus: A Meta-Analysis
ConclusionFollowing PCI with DES, early stent thrombosis was significantly higher in patients with ITDM. However, late and very late stent thromboses were not significantly different in patients with type 2 diabetes mellitus who were treated with or without insulin. Comparison with individual DES was not sufficiently powerful to reach a conclusion. (Source: Diabetes Therapy)
Source: Diabetes Therapy - April 11, 2018 Category: Endocrinology Source Type: research

Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance
AbstractIntroductionTeneligliptin is a novel oral dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus (T2DM). Safety and efficacy of teneligliptin have been demonstrated in clinical studies; however, data supporting its use in patients with moderate or severe renal impairment are limited. This interim analysis of a post-marketing surveillance of teneligliptin, exploRing the long-term efficacy and safety included cardiovascUlar events in patients with type 2 diaBetes treated bY teneligliptin in the real-world (RUBY), aims to verify the long-term safety and efficacy of teneligliptin in Japanese pat...
Source: Diabetes Therapy - April 10, 2018 Category: Endocrinology Source Type: research

Author Correction: Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study
Author Correction to: Diabetes Ther (2018) 9:363 –371 (Source: Diabetes Therapy)
Source: Diabetes Therapy - April 10, 2018 Category: Endocrinology Source Type: research

Efficacy and Safety of Rapid-Acting Insulin Analogs in Special Populations with Type 1 Diabetes or Gestational Diabetes: Systematic Review and Meta-Analysis
ConclusionRapid-acting insulin analogs appear generally safe and effective in these special populations; however, additional trials would be helpful.FundingNovo Nordisk A/S. (Source: Diabetes Therapy)
Source: Diabetes Therapy - April 5, 2018 Category: Endocrinology Source Type: research

Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
ConclusionThe combination of a GLP-1 agonist and an SGLT2-inhibitor has additive effects on lowering HbA1c and systolic blood pressure, body weight and cardiac risk and has the potential to synergistically reduce cardiovascular events and decelerate renal decompensation. A large prospective study of this combination is needed to prove that this synergism, especially as it applies to cardiac risk factors, cardiac events and mortality and preservation of renal function, is proven. (Source: Diabetes Therapy)
Source: Diabetes Therapy - April 5, 2018 Category: Endocrinology Source Type: research

A Retrospective Cohort Study of Patients with Type 2 Diabetes in China: Associations of Hypoglycemia with Health Care Resource Utilization and Associated Costs
ConclusionHypoglycemia in diabetes patients was associated with increased healthcare resource utilization and health-related expenditure, especially for patients on insulin treatment. Insulin treatment regimens should be more individualized and account for hypoglycemia risk. (Source: Diabetes Therapy)
Source: Diabetes Therapy - April 5, 2018 Category: Endocrinology Source Type: research

Basal –Bolus Insulin Therapy with Gla-300 During Hospitalization Reduces Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study
ConclusionIn type 2 diabetic patients, reduction in the incidence of CGM-estimated nocturnal hypoglycemia by BBT under tightly controlled diet therapy was higher with Gla-300 than with Gla-100.Trial RegistrationUMIN clinical trials registry (UMIN000023360). (Source: Diabetes Therapy)
Source: Diabetes Therapy - April 4, 2018 Category: Endocrinology Source Type: research

Is a Previously or Currently Reduced Testosterone Level in Male Patients with Type 2 Diabetes Mellitus a Risk Factor for the Development of Coronary Artery Disease? A Systematic Review and Meta-analysis
ConclusionA previously or currently reduced testosterone level was not found to be statistically significantly associated with a high risk of CAD/cardiovascular disease in male patients with T2DM. However, the difference in risk between the T2DM patients with low and normal testosterone levels was observed to approach statistical significance. (Source: Diabetes Therapy)
Source: Diabetes Therapy - April 4, 2018 Category: Endocrinology Source Type: research

A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes
The objective was to assess the relative efficacy and safety of semaglutide QW vs GLP-1 RAs in Japanese patient s with type 2 diabetes (T2DM), with a specific focus on the comparison between semaglutide 0.5 mg QW and dulaglutide 0.75 mg QW.MethodsA systematic review (SR) and supplementary Japanese searches were conducted to identify trials of GLP-1 RAs in Japanese patients on diet and exercise, who have previously received 0 –1 oral antidiabetic drugs (OADs). Data at 52–56 weeks were extracted for the following outcomes (feasible for analysis in an NMA): glycated hemoglobin (HbA1c), fasting plasm...
Source: Diabetes Therapy - March 24, 2018 Category: Endocrinology Source Type: research

Relative Contribution of Fasting and Postprandial Blood Glucose in Overall Glycemic Control: Post Hoc Analysis of a Phase IV Randomized Trial
AbstractIntroductionFew prospective clinical trials have investigated the role of fasting blood glucose (FBG) and/or postprandial glucose (PPG) in assessing overall glycemic control by using different insulin regimens. In the present post hoc analysis, we assessed the contribution of FBG and/or PPG in overall glycemic control in Chinese patients under insulin treatment.MethodsCLASSIFY is a phase IV, randomized, open-label, 26-week, parallel-arm, treat-to-target, multinational, controlled study in patients with type 2 diabetes mellitus to compare the efficacy and safety of insulin lispro mix 25 (LM25) and insulin lispro mix...
Source: Diabetes Therapy - March 24, 2018 Category: Endocrinology Source Type: research

Basal Insulin Intensification in Patients with Type 2 Diabetes: A Review
This article discusses the rationale, advantages, disadvantages, and implementation of currently available strategies for basal insulin treatment intensification in patients with T2D.Funding: Sanofi US, Inc. (Source: Diabetes Therapy)
Source: Diabetes Therapy - March 24, 2018 Category: Endocrinology Source Type: research

Author Correction: Clinical Benefit of Basal Insulin Analogue Treatment in Persons with Type 2 Diabetes Inadequately Controlled on Prior Insulin Therapy: A Prospective, Noninterventional, Multicenter Study
Discussion’ section was incorrectly published. (Source: Diabetes Therapy)
Source: Diabetes Therapy - March 22, 2018 Category: Endocrinology Source Type: research

The Postprandial-to-Fasting Serum C-Peptide Ratio is a Predictor of Response to Basal Insulin-Supported Oral Antidiabetic Drug(s) Therapy: A Retrospective Analysis
AbstractIntroductionBasal insulin is widely recommended for the treatment of type 2 diabetes mellitus (T2DM) patients who are unable to achieve glycemic control with oral antidiabetic drug(s) (OADs). However, some patients are still unable to control their blood glucose levels even when on basal insulin-supported OAD(s) therapy (BOT). The aim of this study was to investigate the factor(s) predicting patient response to BOT.MethodsA total of 212 patients with T2DM, ranging in age from 18 to 65  years, admitted to the university hospital of Sun Yat-sen University, Guangzhou, China, were enrolled in the study between Jan...
Source: Diabetes Therapy - March 21, 2018 Category: Endocrinology Source Type: research

Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States
AbstractIntroductionThe National Health and Nutrition Examination Surveys show that many people with type 2 diabetes (T2D) in the USA fail to achieve recommended treatment targets. In the SUSTAIN 7 randomized controlled trial, once-weekly semaglutide (0.5 and 1.0  mg) was superior to comparative doses of dulaglutide (0.75 and 1.5 mg) in reducing glycated hemoglobin (HbA1c) and body weight in people with T2D. The present study estimated the cost per patient achieving HbA1c treatment targets and weight loss responses with once-weekly semaglutide and dulaglut ide in the USA.MethodsNumbers needed to treat and annual ...
Source: Diabetes Therapy - March 19, 2018 Category: Endocrinology Source Type: research

Clinical and Cost Implications of Insulin Degludec in Patients with Type 1 Diabetes and Problematic Hypoglycemia: A Quality Improvement Project
AbstractIntroductionTo assess the real-life clinical benefits and cost implications of switching from another basal insulin to insulin degludec (degludec) in patients with type 1 diabetes (T1D) on basal –bolus regimens with recurrent hypoglycemia and/or hypoglycemia unawareness.MethodsPatients with T1D who were aged  ≥ 18 years, were on a basal–bolus regimen, and had switched to degludec plus bolus insulin for at least 6 months were included. Patients had to have switched to degludec as a result of recurrent hypoglycemia and/or hypoglycemia unawareness.ResultsSix months of follow-up d...
Source: Diabetes Therapy - March 16, 2018 Category: Endocrinology Source Type: research

Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions
ConclusionsWithin the FAERS, the association between HF and DPP4is was biased by stimulated reporting, implying that the publication of the SAVOR-TIMI trial and the subsequent regulatory warnings primed clinicians to report HF events in DPP4i users as drug-related AEs. The rate of HF associated with DPP4is was moderated when they were used in combination with SGLT2 inhibitors. (Source: Diabetes Therapy)
Source: Diabetes Therapy - March 16, 2018 Category: Endocrinology Source Type: research

Similar Efficacy and Safety of Basaglar ® and Lantus ® in Patients with Type 2 Diabetes in Age Groups ( & lt;  65 Years, ≥ 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study
AbstractIntroductionTo compare efficacy and safety of Basaglar® [insulin glargine 100  units/mL; LY insulin glargine (LY IGlar)] to Lantus® [insulin glargine 100  units/mL; SA insulin glargine (SA IGlar)] in older (≥ 65 years) or younger (
Source: Diabetes Therapy - March 14, 2018 Category: Endocrinology Source Type: research

Changing Patients ’ Treatment Preferences and Values with a Decision Aid for Type 2 Diabetes Mellitus: Results from the Treatment Arm of a Randomized Controlled Trial
This study investigates the impact of a values-focused patient decision aid (PDA) for T2DM antihyperglycemic agent intensification on patient values related to domains important in decision-making and preferred treatments.MethodsPatients with poorly controlled T2DM who were taking a metformin-containing regimen were recruited through physicians  to access a PDA presenting evidence-based information on T2DM and antihyperglycemic agent class options. Participants’ preferences for treatment, decision-making, and the relative importance they placed on various values related to treatment options (e.g., dosing, weight...
Source: Diabetes Therapy - March 13, 2018 Category: Endocrinology Source Type: research

Pioglitazone Improved Insulin Sensitivity and First Phase Insulin Secretion Among Obese and Lean People with Diabetes: A Multicenter Clamp Study
AbstractIntroductionTo investigate the effects of pioglitazone (PIO) on insulin resistance and first phase insulin secretion among obese and lean Chinese people with type 2 diabetes mellitus (T2DM).MethodsSixty-eight drug-na ïve patients with T2DM were treated with PIO for 16 weeks. Before and after the treatment, insulin sensitivity was evaluated by the euglycemic hyperinsulinemic clamp test. Plasma insulin levels at 0, 3, 5, 7, and 10 min during intravenous glucose tolerance test were determined to calculate the fi rst phase insulin secretion and pancreatic β-cell function. Circulating adiponectin lev...
Source: Diabetes Therapy - March 13, 2018 Category: Endocrinology Source Type: research

Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study
ConclusionsThis real-world analysis suggests differences exist in persistence between patients treated with various GLP-1 RAs. Among the investigated treatments, patients prescribed exBID recorded the lowest and those prescribed DULA the highest persistence with therapy.FundingEli Lilly and Co., Indianapolis, IN, USA. (Source: Diabetes Therapy)
Source: Diabetes Therapy - March 10, 2018 Category: Endocrinology Source Type: research

Insulin Glargine Combined with Oral Antidiabetic Drugs for Asians with Type 2 Diabetes Mellitus: A Pooled Analysis to Identify Predictors of Dose and Treatment Response
AbstractIntroductionIn Asia, patients with type 2 diabetes mellitus (T2DM) often have suboptimal glycemic control for many years prior to initiating basal insulin. Active titration of basal insulin is also required to improve glycemic outcomes. This pooled analysis was conducted to determine the impact of patient baseline covariates on the required dose of basal insulin and treatment response, for the improved management of Asian patients with T2DM.MethodsData on insulin-na ïve Asian patients with T2DM who initiated and fully titrated insulin glargine 100 U/mL (Gla-100) for ≥ 20 weeks were pooled fro...
Source: Diabetes Therapy - March 9, 2018 Category: Endocrinology Source Type: research

Perspectives of Patients with Insulin-Treated Type 1 and Type 2 Diabetes on Hypoglycemia: Results of the HAT Observational Study in Central and Eastern European Countries
ConclusionHypoglycemia impacts patients ’ personal and social functioning, reduces productivity, and results in additional costs, both direct (related to increased use of healthcare resources) and indirect (related to absenteeism.FundingNovo Nordisk. (Source: Diabetes Therapy)
Source: Diabetes Therapy - March 9, 2018 Category: Endocrinology Source Type: research

Adverse Drug Events Associated with Low-Dose (10  mg) Versus High-Dose (25 mg) Empagliflozin in Patients Treated for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
ConclusionsThe incidence of ADEs was not significantly different in T2DM patients receiving 10 versus 25  mg empagliflozin as monotherapy or as add-on to metformin or other anti-diabetic drugs during a shorter or longer follow-up period. However, genital and UTIs were more common in female patients with T2DM irrespective of empagliflozin dosage. (Source: Diabetes Therapy)
Source: Diabetes Therapy - March 9, 2018 Category: Endocrinology Source Type: research

Factors That Influence Pancreatic Beta Cell Function and Insulin Resistance in Newly Diagnosed Type 2 Diabetes Patients: A Sub-Analysis of the MARCH Trial
AbstractIntroductionThe Metformin and Acarbose in Chinese as the initial Hypoglycemic treatment (MARCH) trial has demonstrated a similar efficacy in HbA1c reduction between acarbose and metformin treatments in newly diagnosed type 2 diabetes mellitus (T2DM) patients. The current sub-analysis of the MARCH trail aims to evaluate the baseline characteristics that may influence the improvement of pancreatic β-cell function and insulin resistance after acarbose therapy in Chinese patients with newly diagnosed T2DM.MethodsOf the 784 patients who entered the MARCH trail, 391 were assigned to the acarbose therapy group; 304 o...
Source: Diabetes Therapy - March 9, 2018 Category: Endocrinology Source Type: research

Adherence to Insulin, Emotional Distress, and Trust in Physician Among Patients with Diabetes: A Cross-Sectional Study
AbstractIntroductionType 2 diabetes represents a significant public health issue, with increasing prevalence in developing countries while adherence to insulin treatment remains a challenge. No studies have evaluated the relationship between adherence to insulin, diabetes-related distress, and trust in physician among persons with diabetes. Our objectives were to evaluate treatment adherence to insulin, emotional distress (using the Problem Areas in Diabetes Questionnaire, PAID), trust in physician, and to examine associations between them among Lebanese patients with diabetes.MethodsThis cross-sectional study, conducted i...
Source: Diabetes Therapy - March 8, 2018 Category: Endocrinology Source Type: research

Herpes Zoster and Diabetes Mellitus: A Review
AbstractAccumulating evidence suggests that diabetes mellitus (DM) represents an important risk factor for both herpes zoster and post-herpetic neuralgia. Moreover, post-herpetic neuralgia appears to be more severe and persistent in diabetic patients. On the other hand, a novel vaccine against varicella-zoster virus (VZV) was recently introduced in clinical practice. Given the increased risk and severity of herpes zoster infection in patients with DM, this vaccine might be useful in this population. However, there are limited data regarding the efficacy and safety of vaccination against herpes zoster in the diabetic popula...
Source: Diabetes Therapy - March 8, 2018 Category: Endocrinology Source Type: research

Effects of Insulin Lispro Mix 25 and Insulin Lispro Mix 50 on Postprandial Glucose Excursion in Patients with Type 2 Diabetes: A Prospective, Open-Label, Randomized Clinical Trial
ConclusionsLM50 may provide better glycemic excursion control after breakfast and dinner than LM25 in T2DM patients.Trial Registrationhttp://www.chictr.org.cn # ChiCTR-TTRCC-12002516.FundingLilly Suzhou Pharmaceutical Co., Ltd. (Shanghai Branch, China) and National Key Program of Clinical Science of China (WBYZ 2011-873). (Source: Diabetes Therapy)
Source: Diabetes Therapy - March 8, 2018 Category: Endocrinology Source Type: research

EADSG Guidelines: Insulin Therapy in Diabetes
Executive Summary and RecommendationsA diagnosis of diabetes or hyperglycemia should be confirmed prior to ordering, dispensing, or administering insulin(A).Insulin is the primary treatment in all patients with type 1 diabetes mellitus (T1DM)(A).Typically, patients with T1DM will require initiation with multiple daily injections at the time of diagnosis. This is usually short-acting insulin or rapid-acting insulin analogue given 0 to 15  min before meals together with one or more daily separate injections of intermediate or long-acting insulin. Two or three premixed insulin injections per day may be used(A).The target...
Source: Diabetes Therapy - March 5, 2018 Category: Endocrinology Source Type: research

Author Correction: Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study
AbstractThe original version of this article unfortunately contained a mistake. (Source: Diabetes Therapy)
Source: Diabetes Therapy - March 5, 2018 Category: Endocrinology Source Type: research

User Performance Evaluation of Four Blood Glucose Monitoring Systems Applying ISO 15197:2013 Accuracy Criteria and Calculation of Insulin Dosing Errors
In this study, user performance was evaluated for four SMBG systems on the basis of ISO 15197:2013, and possibly related insulin dosing errors were calculated. Additionally, accuracy was assessed in the hands of study personnel.MethodsAccu-Chek® Performa Connect (A), Contour® plus ONE (B), FreeStyle Optium Neo (C), and OneTouch Select® Plus (D) were evaluated with one test strip lot. After familiarization with the systems, subjects collected a capillary blood sample and performed an SMBG measurement. Study personnel observed the subjects ’ measurement technique. Then, study personnel performed SMBG measur...
Source: Diabetes Therapy - March 3, 2018 Category: Endocrinology Source Type: research

Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes
AbstractIntroductionEmpagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, ameliorates hyperglycemia in patients with type 2 diabetes (T2D) by inducing sustained glucosuria. Empagliflozin treatment was previously associated with a transient increase in 24-h urine volume in Caucasian patients with T2D, however comparable evidence in Japanese T2D individuals is scarce. We therefore assessed acute and chronic changes in 24-h urine volume and fluid intake with empagliflozin in Japanese patients with T2D.MethodsIn this randomized, double-blind, placebo-controlled, parallel-group, multiple-dose, 4-week trial, 100 Ja...
Source: Diabetes Therapy - February 27, 2018 Category: Endocrinology Source Type: research

Insulin Matters: A Practical Approach to Basal Insulin Management in Type 2 Diabetes
This article summarizes the panel recommendations. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 23, 2018 Category: Endocrinology Source Type: research

A Real-World Anti-Diabetes Medication Cost Comparison Between Premixed Insulin Analogs and Long-Acting Insulin Analogs in Chinese Patients with Type 2 Diabetes: A Retrospective Database Analysis
ConclusionAmong Chinese T2DM insulin-na ïve patients, those who initiated premixed insulin had a lower per-day antidiabetic medication cost than those who initiated long-acting insulin.FundingLilly Suzhou Pharmaceutical Co. Ltd, China. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 23, 2018 Category: Endocrinology Source Type: research

Clinical Benefit of Basal Insulin Analogue Treatment in Persons with Type 2 Diabetes Inadequately Controlled on Prior Insulin Therapy: A Prospective, Noninterventional, Multicenter Study
AbstractIntroductionBasal insulin analogues offer persons with type 2 diabetes mellitus (T2DM) adequate glycemic control combined with a favorable safety profile. BASAL-BALI —a prospective, noninterventional, multicenter disease registry—assessed the effectiveness and safety of basal insulin analogues in adult Serbians with T2DM previously inadequately controlled on other insulin types.MethodsThe primary objective was to assess the reduction in glycated hemoglobin (HbA1c) from basal insulin analogue initiation to the end of a 6-month observation period. Data collection was performed at three study visits: basel...
Source: Diabetes Therapy - February 19, 2018 Category: Endocrinology Source Type: research

Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population
In this study, only 5.7% of patients with an eGFR of
Source: Diabetes Therapy - February 19, 2018 Category: Endocrinology Source Type: research

Diabetes in the Elderly
AbstractThe elderly are an important and distinct yet heterogeneous group of persons living with diabetes. The elderly have a unique biomedical, psychological, and social constitution. Their needs are different from those of younger adults. This implies that special care must be taken while evaluating and planning their nursing and management. Diabetes management in the elderly should focus on prevention and limitation of geriatric syndromes (medical conditions encountered in elderly persons), hypoglycemia (low blood glucose), and neurocognitive dysfunction (impairment in the functioning of the nervous system and brain). T...
Source: Diabetes Therapy - February 19, 2018 Category: Endocrinology Source Type: research

Analysis of Postprandial Glycemia in Relation to Metabolic Compensation and Other Observed Parameters of Outpatients with Type 2 Diabetes Mellitus in the Czech Republic
AbstractIntroductionThe goal of the study was to determine the level of metabolic compensation expressed by glycosylated hemoglobin, fasting plasma glucose, and postprandial glucose as determined after a standardized breakfast; further, to evaluate interrelationships between the studied parameters and postprandial glucose levels.MethodsThe study included 1055 patients with type 2 diabetes mellitus. Their fasting plasma glucose and postprandial glucose were measured before and after a standardized breakfast. Attending diabetologists completed a uniform questionnaire that included demographic data, type of antidiabetic treat...
Source: Diabetes Therapy - February 19, 2018 Category: Endocrinology Source Type: research

Efficacy and Safety of Teneligliptin 40  mg in Type 2 Diabetes: A Pooled Analysis of Two Phase III Clinical Studies
ConclusionIncreasing the dosage of teneligliptin from 20 to 40  mg/day has potential as a well-tolerated and effective option for treating type 2 diabetes.FundingMitsubishi Tanabe Pharma Corporation. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 12, 2018 Category: Endocrinology Source Type: research

Diabetic Painful Neuropathy and Restless Legs Syndrome in Diabetes
AbstractRestless legs syndrome (RLS) and diabetic painful neuropathy (DPN) are two distinct neurological conditions, which share many similarities. As RLS occurs frequently in persons with diabetes, the differential diagnosis and management of RLS and DPN may pose a clinical challenge. This communication describes the etiopathogenesis, clinical features, investigations, and treatment of both conditions. It highlights the similarities and differences between RLS and DPN, and helps the physician plan a rational clinical and therapeutic approach. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 9, 2018 Category: Endocrinology Source Type: research

Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1  Year: An Open-Label, Non-Randomized, Controlled Study
AbstractIntroductionCarbohydrate restriction markedly improves glycemic control in patients with type 2 diabetes (T2D) but necessitates prompt medication changes. Therefore, we assessed the effectiveness and safety of a novel care model providing continuous remote care with medication management based on biometric feedback combined with the metabolic approach of nutritional ketosis for T2D management.MethodsWe conducted an open-label, non-randomized, controlled, before-and-after 1-year study of this continuous care intervention (CCI) and usual care (UC). Primary outcomes were glycosylated hemoglobin (HbA1c), weight, and me...
Source: Diabetes Therapy - February 7, 2018 Category: Endocrinology Source Type: research

Cost-Effectiveness Analysis of Canagliflozin 300  mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States
ConclusionThese results suggest that canagliflozin 300  mg is likely to provide better health outcomes at a lower overall cost than dapagliflozin 10 mg in patients with T2DM inadequately controlled with metformin from the perspective of the United States health care system.FundingJanssen Scientific Affairs, LLC and Janssen Global Services, LLC. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 6, 2018 Category: Endocrinology Source Type: research

Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment
AbstractPost-liver transplantation diabetes mellitus  (PLTDM) develops in up to 30% of liver transplant recipients and is associated with increased risk of mortality and multiple morbid outcomes. PLTDM is a multicausal disorder, but the main risk factor is the use of immunosuppressive agents of the calcineurin inhibitor (CNI) family (tacrolimus and c yclosporine). Additional factors, such as pre-transplant overweight, nonalcoholic steatohepatitis and hepatitis C virus infection, may further increase risk of developing PLTDM. A diagnosis of PLTDM should be established only after doses of CNI and steroids are stabl...
Source: Diabetes Therapy - February 6, 2018 Category: Endocrinology Source Type: research

Changes in Heart Rate Associated with Exenatide Once Weekly: Pooled Analysis of Clinical Data in Patients with Type 2 Diabetes
ConclusionsSmall increases in heart rate were associated with exenatide QW, exenatide BID, and liraglutide treatments but reverted to baseline after discontinuation. Increases were more likely in patients with a low baseline heart rate. The clinical relevance of these heart rate increases is unknown but will be clarified by several ongoing and recently completed cardiovascular outcome studies. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 3, 2018 Category: Endocrinology Source Type: research

Rapid-acting and Regular Insulin are Equal for High Fat-Protein Meal in Individuals with Type 1 Diabetes Treated with Multiple Daily Injections
AbstractIntroductionThe fat and protein content can impact late postprandial glycemia; therefore, prolonged insulin boluses for high-fat/-protein meals are recommended for patients with type 1 diabetes on insulin pump therapy. It is not clear how to translate these findings to multiple daily injection (MDI) therapy. We hypothesized that regular insulin with a slower onset and a longer duration of action might be advantageous for such meals.MethodsTwenty-five patients with well-controlled type 1 diabetes (mean HbA1c 6.8%, 51  mmol/mol, no episodes of hypoglycemia) on MDI therapy, aged 27.9 ± 4.3 y...
Source: Diabetes Therapy - January 17, 2018 Category: Endocrinology Source Type: research